MVZ fuer Haematologie und Onkologie Koeln Am Sachsenring GmbH
- Address
- Sachsenring 69, Neustadt-Sued, 50677 Cologne, Germany
Oncology Clinical Research – Lung Cancer Focus
The MVZ fuer Haematologie und Onkologie Koeln Am Sachsenring GmbH conducts cutting‑edge trials in the therapeutic area of Neoplasms, concentrating on advanced forms of non‑small cell lung cancer. Researchers aim to improve outcomes by testing new immunotherapy combinations, targeted agents, and dose‑optimization strategies.
- Evaluating novel combination regimens that pair antibody‑drug conjugates with immune checkpoint inhibitors.
- Investigating targeted therapy for patients with KRAS G12C mutations.
- Optimizing dosing and safety of emerging agents in first‑line treatment settings.
With four active studies led by four investigators, the site in Cologne, Germany, is advancing personalized cancer care by focusing on biomarkers such as PD‑L1 and TROP2, and by comparing new treatments against standard pembrolizumab‑based regimens.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AstraZeneca AB2active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MVZ fuer Haematologie und Onkologie Koeln Am Sachsenring GmbH
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Small Cell Lung Cancer with PD-L1 < 1% | AstraZeneca AB | Phase III | Not Yet Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Infliximab | 2 | Unknown | 2024-06-13 | 2025-01-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.